Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers

David E. Nix, John H. Wilton, Judith Hyatt, Jennifer Thomas, Laura C. Strenkoski-Nix, Alan Forrest, Jerome J. Schentag

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The pharmacokinetics (PK) and pharmacodynamics (PD) of cefotaxime and ofloxacin and of their combination were examined in a three-period randomized crossover study involving 12 healthy adults. The PK of cefotaxime and ofloxacin were modeled. PD was assessed from the predicted concentrations in serum and serum untrafiltrate inhibitory titers for 10 test organisms. An inhibitory sigmoid E(max) model based on the probability of bacterial growth was used, where Emax = 1 and EC50 is the concentration resulting in a 50% probability of growth. The total body clearance (CL(T) and volume of distribution at steady state (V(SS)) for cefotaxime were 0.236 liters/kg/h and 0.207 liters/kg, respectively, for the monotherapy and 0.231 liters/kg/h and 0.208 liters/kg for the combination therapy. Ofloxacin exhibited PK parameters of 0.143 liters/kg/h for CL(T) and 1.20 liters/kg for V(SS) following the monotherapy and of 0.141 liters/kg/h for CL(T) and 1.16 liters/kg for V(SS) following combination therapy. For the combination therapy, an interaction term, θ, defined the type and relative extent of interaction. The range of observed θ values (-0.033 to 0.067) is consistent with an additive PD interaction according to standards similar to those used for the in vitro fractional inhibitory concentration index.

Original languageEnglish (US)
Pages (from-to)1108-1114
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume41
Issue number5
StatePublished - May 1997

Fingerprint

Ofloxacin
Cefotaxime
Pharmacokinetics
Serum
Sigmoid Colon
Growth
Cross-Over Studies
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Nix, D. E., Wilton, J. H., Hyatt, J., Thomas, J., Strenkoski-Nix, L. C., Forrest, A., & Schentag, J. J. (1997). Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrobial Agents and Chemotherapy, 41(5), 1108-1114.

Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. / Nix, David E.; Wilton, John H.; Hyatt, Judith; Thomas, Jennifer; Strenkoski-Nix, Laura C.; Forrest, Alan; Schentag, Jerome J.

In: Antimicrobial Agents and Chemotherapy, Vol. 41, No. 5, 05.1997, p. 1108-1114.

Research output: Contribution to journalArticle

Nix, DE, Wilton, JH, Hyatt, J, Thomas, J, Strenkoski-Nix, LC, Forrest, A & Schentag, JJ 1997, 'Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers', Antimicrobial Agents and Chemotherapy, vol. 41, no. 5, pp. 1108-1114.
Nix, David E. ; Wilton, John H. ; Hyatt, Judith ; Thomas, Jennifer ; Strenkoski-Nix, Laura C. ; Forrest, Alan ; Schentag, Jerome J. / Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. In: Antimicrobial Agents and Chemotherapy. 1997 ; Vol. 41, No. 5. pp. 1108-1114.
@article{a082f1f50f7e47f0970888ee9fdd16b8,
title = "Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers",
abstract = "The pharmacokinetics (PK) and pharmacodynamics (PD) of cefotaxime and ofloxacin and of their combination were examined in a three-period randomized crossover study involving 12 healthy adults. The PK of cefotaxime and ofloxacin were modeled. PD was assessed from the predicted concentrations in serum and serum untrafiltrate inhibitory titers for 10 test organisms. An inhibitory sigmoid E(max) model based on the probability of bacterial growth was used, where Emax = 1 and EC50 is the concentration resulting in a 50{\%} probability of growth. The total body clearance (CL(T) and volume of distribution at steady state (V(SS)) for cefotaxime were 0.236 liters/kg/h and 0.207 liters/kg, respectively, for the monotherapy and 0.231 liters/kg/h and 0.208 liters/kg for the combination therapy. Ofloxacin exhibited PK parameters of 0.143 liters/kg/h for CL(T) and 1.20 liters/kg for V(SS) following the monotherapy and of 0.141 liters/kg/h for CL(T) and 1.16 liters/kg for V(SS) following combination therapy. For the combination therapy, an interaction term, θ, defined the type and relative extent of interaction. The range of observed θ values (-0.033 to 0.067) is consistent with an additive PD interaction according to standards similar to those used for the in vitro fractional inhibitory concentration index.",
author = "Nix, {David E.} and Wilton, {John H.} and Judith Hyatt and Jennifer Thomas and Strenkoski-Nix, {Laura C.} and Alan Forrest and Schentag, {Jerome J.}",
year = "1997",
month = "5",
language = "English (US)",
volume = "41",
pages = "1108--1114",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers

AU - Nix, David E.

AU - Wilton, John H.

AU - Hyatt, Judith

AU - Thomas, Jennifer

AU - Strenkoski-Nix, Laura C.

AU - Forrest, Alan

AU - Schentag, Jerome J.

PY - 1997/5

Y1 - 1997/5

N2 - The pharmacokinetics (PK) and pharmacodynamics (PD) of cefotaxime and ofloxacin and of their combination were examined in a three-period randomized crossover study involving 12 healthy adults. The PK of cefotaxime and ofloxacin were modeled. PD was assessed from the predicted concentrations in serum and serum untrafiltrate inhibitory titers for 10 test organisms. An inhibitory sigmoid E(max) model based on the probability of bacterial growth was used, where Emax = 1 and EC50 is the concentration resulting in a 50% probability of growth. The total body clearance (CL(T) and volume of distribution at steady state (V(SS)) for cefotaxime were 0.236 liters/kg/h and 0.207 liters/kg, respectively, for the monotherapy and 0.231 liters/kg/h and 0.208 liters/kg for the combination therapy. Ofloxacin exhibited PK parameters of 0.143 liters/kg/h for CL(T) and 1.20 liters/kg for V(SS) following the monotherapy and of 0.141 liters/kg/h for CL(T) and 1.16 liters/kg for V(SS) following combination therapy. For the combination therapy, an interaction term, θ, defined the type and relative extent of interaction. The range of observed θ values (-0.033 to 0.067) is consistent with an additive PD interaction according to standards similar to those used for the in vitro fractional inhibitory concentration index.

AB - The pharmacokinetics (PK) and pharmacodynamics (PD) of cefotaxime and ofloxacin and of their combination were examined in a three-period randomized crossover study involving 12 healthy adults. The PK of cefotaxime and ofloxacin were modeled. PD was assessed from the predicted concentrations in serum and serum untrafiltrate inhibitory titers for 10 test organisms. An inhibitory sigmoid E(max) model based on the probability of bacterial growth was used, where Emax = 1 and EC50 is the concentration resulting in a 50% probability of growth. The total body clearance (CL(T) and volume of distribution at steady state (V(SS)) for cefotaxime were 0.236 liters/kg/h and 0.207 liters/kg, respectively, for the monotherapy and 0.231 liters/kg/h and 0.208 liters/kg for the combination therapy. Ofloxacin exhibited PK parameters of 0.143 liters/kg/h for CL(T) and 1.20 liters/kg for V(SS) following the monotherapy and of 0.141 liters/kg/h for CL(T) and 1.16 liters/kg for V(SS) following combination therapy. For the combination therapy, an interaction term, θ, defined the type and relative extent of interaction. The range of observed θ values (-0.033 to 0.067) is consistent with an additive PD interaction according to standards similar to those used for the in vitro fractional inhibitory concentration index.

UR - http://www.scopus.com/inward/record.url?scp=0030902086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030902086&partnerID=8YFLogxK

M3 - Article

C2 - 9145877

AN - SCOPUS:0030902086

VL - 41

SP - 1108

EP - 1114

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -